Navidea Biopharmaceuticals Inc (OTCPK:NAVB)
$ 0.036 -0.002 (-5.26%) Market Cap: 3.60 Mil Enterprise Value: 1.20 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q1 2020 Navidea Biopharmaceuticals Inc Earnings Call Transcript

May 14, 2020 / 09:00PM GMT
Release Date Price: $0.9614 (+0.09%)
Operator

Greetings, and welcome to the Navidea Biopharmaceuticals Quarter 1 2020 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Jed Latkin, CEO. Thank you. Please begin.

Jed A. Latkin
Navidea Biopharmaceuticals, Inc. - CEO, COO, CFO & Director

Thank you, Daryl. I appreciate the introduction. Good afternoon, and welcome, everyone, to Navidea's First Quarter of 2020 Earnings Call. I am Jed Latkin, Chief Executive Officer of Navidea Biopharmaceuticals. This call will cover Navidea's financial and operating results for the first quarter of 2020, which ended on March 31, 2020, along with a discussion of goals and milestones for the rest of the year. Following our prepared remarks, we will open up the conference call to a question-and-answer session. With me on our call today is our Chief Medical Officer, Dr. Mike Rosol; and our Director of Finance and Administration, Erika Eves.

But before we begin our formal remarks, I would like to remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot